Apex Biotechnology Corp. (TPE:1733)

G1 Therapeutics Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	583.5	532.69	382.05	331.71	555.33	786.95
Trading Asset Securities	91.24	66.1	61.87	65.83	69.72	36.01
Cash & Short-Term Investments	674.74	598.78	443.91	397.53	625.05	822.96
Cash Growth	55.97%	34.89%	11.67%	-36.40%	-24.05%	2.48%
Accounts Receivable	408.01	346.64	288.39	486.77	474.41	325.41
Other Receivables	9.5	8.08	5.72	10.12	13.97	17.28
Receivables	417.51	354.72	294.11	496.89	488.38	342.68
Inventory	540.3	662.49	747.71	739.25	628.59	504.54
Prepaid Expenses	-	24.78	18.51	19	11.06	13.47
Other Current Assets	18.44	2.29	2.4	1.81	6.78	0.83
Total Current Assets	1,651	1,643	1,507	1,654	1,760	1,684
Property, Plant & Equipment	670.45	695.81	720.59	766.08	794.12	827.81
Long-Term Investments	6.2	-	-	-	-	-
Other Intangible Assets	34.96	39.6	44.22	69.14	106.48	128.92
Long-Term Deferred Tax Assets	6.07	9.24	4.24	3.62	0.43	2.39
Other Long-Term Assets	32.93	32.23	21.32	21.38	9.58	7.86
Total Assets	2,402	2,420	2,297	2,515	2,670	2,651
Accounts Payable	189.24	239.03	156.22	289.69	343.89	245
Accrued Expenses	-	142.25	133.43	150.55	148.07	125.41
Short-Term Debt	-	-	30	50	150	-
Current Portion of Long-Term Debt	-	-	-	-	-	389.88
Current Portion of Leases	8.49	9.03	7.2	8.01	6.88	5.56
Current Income Taxes Payable	25.92	24.52	46.24	36.92	40.12	70.28
Current Unearned Revenue	13.8	58.28	6.6	29.04	93.06	42.61
Other Current Liabilities	263.34	4.68	3.67	6.35	3.87	4.7
Total Current Liabilities	500.78	477.78	383.35	570.55	785.89	883.43
Long-Term Leases	105.21	113.93	116.2	122.67	127.66	118.28
Long-Term Deferred Tax Liabilities	4.08	3.54	0.04	3.1	2.88	1.21
Other Long-Term Liabilities	0.43	0.47	0.48	0.49	0.48	0.48
Total Liabilities	610.49	595.7	500.07	696.81	916.91	1,005
Common Stock	999.5	999.5	999.5	999.5	999.5	999.5
Additional Paid-In Capital	68.37	68.37	68.37	68.37	68.37	66.78
Retained Earnings	714.8	744.06	718.87	739.95	682.34	586.9
Treasury Stock	-	-	-	-	-	-12.25
Comprehensive Income & Other	7.8	11.67	9.69	9.51	2.52	4.45
Total Common Equity	1,790	1,824	1,796	1,817	1,753	1,645
Minority Interest	0.64	0.63	0.5	0.57	0.82	0.78
Shareholders' Equity	1,791	1,824	1,797	1,818	1,754	1,646
Total Liabilities & Equity	2,402	2,420	2,297	2,515	2,670	2,651
Total Debt	113.69	122.96	153.4	180.68	284.55	513.72
Net Cash (Debt)	561.05	475.83	290.52	216.85	340.5	309.24
Net Cash Growth	85.80%	63.79%	33.97%	-36.31%	10.11%	61.63%
Net Cash Per Share	5.59	4.74	2.90	2.15	3.22	2.74
Filing Date Shares Outstanding	98.8	99.95	99.95	99.95	99.95	99.38
Total Common Shares Outstanding	98.8	99.95	99.95	99.95	99.95	99.38
Working Capital	1,150	1,165	1,123	1,084	973.97	801.05
Book Value Per Share	18.12	18.25	17.97	18.18	17.54	16.56
Tangible Book Value	1,756	1,784	1,752	1,748	1,646	1,516
Tangible Book Value Per Share	17.77	17.85	17.53	17.49	16.47	15.26
Land	-	261.68	261.68	261.68	261.68	261.68
Buildings	-	605.02	604.13	604.13	601.96	601.58
Machinery	-	806.49	789.71	777.35	754.25	748.98
Leasehold Improvements	-	-	-	-	-	0.43

Updated Feb 26, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.